Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

被引：3

作者：

Furman, Richard R. ^{[1
]}

Wierda, William G. ^{[2
]}

Schuh, Anna ^{[3
]}

Devereux, Stephen ^{[4
]}

Chaves, Jorge M. ^{[5
]}

Brown, Jennifer R. ^{[6
]}

Hillmen, Peter ^{[7
]}

Martin, Peter ^{[8
]}

Awan, Farrukh T. ^{[9
]}

Stephens, Deborah M. ^{[10
]}

Ghia, Paolo ^{[11
,12
]}

Barrientos, Jacqueline C. ^{[13
]}

Pagel, John M. ^{[14
]}

Woyach, Jennifer ^{[15
]}

Burke, Kathleen ^{[16
]}

Covey, Todd ^{[17
]}

Gulrajani, Michael ^{[18
]}

Hamdy, Ahmed ^{[18
]}

Izumi, Raquel ^{[18
]}

Frigault, Melanie M. ^{[18
]}

Patel, Priti ^{[18
]}

Rothbaum, Wayne ^{[18
]}

Wang, Min Hui ^{[18
]}

O'Brien, Susan M. ^{[19
]}

Byrd, John C. ^{[15
]}

机构：

[1] Weill Cornell Med, New York, NY USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Oxford, Dept Oncol, Oxford, England

[4] NHS Fdn Trust, Kings Coll Hosp, London, England

[5] Northwest Med Specialties PLLC, Tacoma, WA USA

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[7] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[8] Weill Cornell Med New York Presbyterian Hosp, New York, NY USA

[9] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

[10] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[11] Univ Vita Salute San Raffaele, Milan, Italy

[12] IRCCS San Raffaele Sci Inst, Milan, Italy

[13] Hofstra Northwell Sch Med, Hempstead, NY USA

[14] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[15] Ohio State Univ, Columbus, OH 43210 USA

[16] Oncol iMED AstraZeneca, Boston, MA USA

[17] Acerta Pharma, San Francisco, CA USA

[18] Acerta Pharma, San Francisco, CA USA

[19] UC Irvine, Chao Family Comprehens Canc Ctr, Orange, CA USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-128706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3039

引用

页数：5

共 50 条

[21] Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia
Jurczak, Wojciech
Pluta, Andrzej
Wach, Malgorzata
Lysak, Daniel
Kozak, Tomas
Simkovic, Martin
Kriachok, Iryna
Illes, Arpad
de la Serna, Javier
Dolan, Sean
Campbell, Philip
Musuraca, Gerardo
Jacob, Abraham
Avery, Eric J.
Lee, Jae Hoon
Wang, Min Hui
Yu, Ting
Ghia, Paolo
BLOOD, 2021, 138
[22] Phase I trial of lenalidomide in combination with plerixafor for relapsed/refractory chronic lymphocytic leukemia (CLL): follow-up and correlative analysis
Brander, Danielle
Weinberg, J. Brice
Friedman, Daphne
Stewart, Tiffany
Rizzieri, David
LEUKEMIA & LYMPHOMA, 2017, 58 : 35 - 37
[23] Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Awan, Farrukh T.
Schuh, Anna
Brown, Jennifer R.
Furman, Richard R.
Pagel, John M.
Hillmen, Peter
Stephens, Deborah M.
Woyach, Jennifer
Bibikova, Elena
Charuworn, Prista
Frigault, Melanie M.
Hamdy, Ahmed
Izumi, Raquel
Linghu, Bolan
Patel, Priti
Wang, Min Hui
Byrd, John C.
BLOOD ADVANCES, 2019, 3 (09) : 1553 - 1562
[24] A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Ahn, Inhye E.
Zhou, Yinglu
Tyekucheva, Svitlana
Cormier, Hannah
Fernandes, Stacey M.
Montegaard, Josie
Kilcommons, Marykate
Crombie, Jennifer L.
Merryman, Reid W.
Parry, Erin M.
Armand, Philippe
Fisher, David C.
Jacobson, Caron A.
Davids, Matthew S.
Brown, Jennifer R.
BLOOD, 2023, 142
[25] Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Davids, Matthew S.
Hallek, Michael
Wierda, William
Roberts, Andrew W.
Stilgenbauer, Stephan
Jones, Jeffrey A.
Gerecitano, John F.
Kim, Su Young
Potluri, Jalaja
Busman, Todd
Best, Andrea
Verdugo, Maria E.
Cerri, Elisa
Desai, Monali
Hillmen, Peter
Seymour, John F.
CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4371 - 4379
[26] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study
Xu, Wei
Song, Yongping
Wang, Tingyu
Yang, Shenmiao
Liu, Lihong
Hu, Yu
Zhang, Wei
Zhou, Jianfeng
Gao, Sujun
Ding, Kaiyang
Zhang, Huilai
Zhu, Zunmin
Wang, Shunqing
Xu, Bing
Hu, Jianda
Liu, Ting
Ji, Chunyan
Xia, Zhongjun
Li, Yan
Wang, Xin
Bin Zhang
Zhao, Renbin
Li, Jianyong
BLOOD, 2021, 138
[27] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Barr, Paul M.
Hill, Brian T.
Ma, Shuo
Baran, Andrea M.
Bui, Andrew
Meacham, Philip J.
Morrison, Ashley
Liesveld, Jane L.
Mulford, Deborah A.
Sportelli, Peter
Miskin, Hari P.
Weiss, Michael S.
Friedberg, Jonathan W.
Zent, Clive S.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 9 - 10
[28] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 19 - 20
[29] Addition of acalabrutinib to obinutuzumab-venetoclax for treatment of relapsed or refractory chronic lymphocytic leukemia
Stocker, Nicolas
HEMATOLOGIE, 2022, 28 (06): : 256 - 257
[30] Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Woyach, Jennifer A.
Blachly, James S.
Rogers, Kerry A.
Bhat, Seema A.
Jianfar, Mojgan
Lozanski, Gerard
Weiss, David M.
Andersen, Barbara L.
Gulrajani, Michael
Frigault, Melanie M.
Hamdy, Ahmed
Izumi, Raquel
Munugalavadla, Veerendra
Quah, Cheng
Wang, Min-Hui
Byrd, John C.
CANCER DISCOVERY, 2020, 10 (03) : 394 - 405

← 1 2 3 4 5 →